Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
721-740 of 2,251 trials

Multiple Sclerosis: Ocrelizumab Access Study

We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.

Multiple Sclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

HER3-DXd for Advanced Solid Tumors

We are studying a new treatment for patients with locally advanced or metastatic solid tumors to see if it is effective and safe. This trial will help us understand how well it works and its relationship with tumor characteristics.

Locally Advanced or Metastatic Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Infectious Endocarditis: Shorter Antibiotic Treatment Study

We are investigating whether a shorter course of antibiotics is safe and effective for treating left-sided infectious endocarditis caused by specific bacteria. This study also looks at the potential cost benefits of this accelerated treatment.

Infectious Endocarditis≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInfectious Diseases

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Prostate Cancer: [225Ac]Ac-PSMA-R2 Treatment Study

We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.

Advanced Prostate CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: Selpercatinib Access Program

We are providing access to selpercatinib for adults with locally advanced or metastatic solid tumors that have specific genetic changes. This program aims to help patients who may benefit from this targeted treatment.

Various Types of Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Rheumatoid Arthritis: MethMax Trial

We are studying how well methotrexate works for people with active rheumatoid arthritis. The goal is to see if it helps more patients reach remission or low disease activity compared to current treatments.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Deep Burns: Testing denovoSkin™ Graft

We are studying a new skin graft for patients with deep partial and full-thickness burns to see if it helps wounds heal and reduces scarring better than standard treatments. This trial aims to improve recovery outcomes for burn patients.

Deep Partial and Full-Thickness BurnsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatology

Axial Spondyloarthritis: Risankizumab Treatment

We are studying the effects of a new treatment for patients with very early axial spondyloarthritis. The goal is to see if it can reduce disease activity and improve overall function.

Axial Spondyloarthritis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Hemophilia A: Long-Term Follow-Up of BMN 270

We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.

Hemophilia A>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Multiple Myeloma: BGB-11417 Treatment Study

We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Progesterone for Preventing Preterm Birth in Women with Placenta Previa

We are studying whether progesterone can help reduce the risk of preterm birth in women diagnosed with placenta previa. This trial will look at various outcomes, including the timing of birth and any side effects for mothers and babies.

Placenta Previa3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPediatrics

Pancreatic Cancer: Islet Cell Transplantation After Surgery

We are studying the effects of removing part or all of the pancreas and transplanting the patient's own islet cells in patients with pancreatic cancer at high risk for complications. The goal is to see if this approach improves safety and quality of life.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Lung Cancer: IPH5201 and Durvalumab Treatment Study

We are studying a combination of two treatments before and after surgery for patients with early-stage non-small cell lung cancer. The goal is to see if this approach improves tumor response and safety compared to standard treatments.

Non-Small Cell Lung Cancer (NSCLC) Stage II and III1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Childhood Epilepsy: Perampanel Treatment Study

We are studying the effects of perampanel, given with other epilepsy medications, in children under 18. The goal is to see if it helps reduce seizures and improve overall health and development.

Childhood EpilepsyEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyPediatrics

Peripheral T-Cell Lymphoma: New Drug Combinations

We are studying whether combining Beleodaq or Folotyn with standard chemotherapy is more effective for newly diagnosed patients with Peripheral T-Cell Lymphoma. The goal is to see if these combinations improve treatment outcomes compared to standard therapy alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Cardiac Anesthesia: Eleveld Model for Propofol and Remifentanil

We are studying how well a new model predicts drug levels of propofol and remifentanil in patients undergoing heart surgery. This research may help improve anesthesia safety and effectiveness during cardiac procedures.

Heart Disorders1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Linvoseltamab for Relapsed or Refractory AL Amyloidosis

We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.

Relapsed or Refractory Systemic Light Chain Amyloidosis>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Satralizumab for Pediatric Neuromyelitis Optica Spectrum Disorder

We are studying how well satralizumab works and its safety in children aged 2-11 with AQP4 antibody positive neuromyelitis optica spectrum disorder. This research aims to improve treatment options for these young patients.

Neuromyelitis Optica Spectrum Disorder (NMOSD)6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPediatrics